Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.

DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.

Kumar D, Mehta A, Panigrahi MK, Nath S, Saikia KK.

Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):82-89. doi: 10.1016/j.hemonc.2017.09.004. Epub 2017 Oct 18.

2.

Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.

Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JD.

J Hematol Oncol. 2014 Oct 4;7:74. doi: 10.1186/s13045-014-0074-4.

3.

FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

Ardestani MT, Kazemi A, Chahardouli B, Mohammadi S, Nikbakht M, Rostami S, Jalili M, Vaezi M, Alimoghaddam K, Ghavamzadeh A.

Turk J Haematol. 2018 Aug 3;35(3):158-167. doi: 10.4274/tjh.2018.0017. Epub 2018 May 22.

4.

[Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].

Tang SH, Lu Y, Zhang PS, Liu XH, Du XH, Chen D, Sha KY, Li SY, Cao JJ, Chen LG, Zhuang XX, Pei RZ, Tang XW.

Zhonghua Xue Ye Xue Za Zhi. 2018 Jul 14;39(7):552-557. doi: 10.3760/cma.j.issn.0253-2727.2018.07.005. Chinese.

PMID:
30122013
5.

FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.

Tang S, Shen H, Mao X, Dai H, Zhu X, Xue S, Ding Z, Lu J, Wu D, Tang X.

Int J Hematol. 2017 Oct;106(4):552-561. doi: 10.1007/s12185-017-2256-7. Epub 2017 Jun 14.

PMID:
28616699
6.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
7.

FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.

Rezaei N, Arandi N, Valibeigi B, Haghpanah S, Khansalar M, Ramzi M.

Turk J Haematol. 2017 Dec 1;34(4):300-306. doi: 10.4274/tjh.2016.0489. Epub 2017 Mar 15.

8.

DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.

Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030. Epub 2015 Jul 31.

9.

FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.

Wang L, Xu WL, Meng HT, Qian WB, Mai WY, Tong HY, Mao LP, Tong Y, Qian JJ, Lou YJ, Chen ZM, Wang YG, Jin J.

J Zhejiang Univ Sci B. 2010 Oct;11(10):762-70. doi: 10.1631/jzus.B1000052.

10.

Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.

Shamaa S, Laimon N, Aladle DA, Azmy E, Elghannam DM, Salem DA, Taalab MM.

Hematology. 2014 Jan;19(1):22-30. doi: 10.1179/1607845413Y.0000000085. Epub 2013 Nov 25.

PMID:
23540998
11.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
12.

CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.

Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H.

Hum Pathol. 2013 Oct;44(10):2038-46. doi: 10.1016/j.humpath.2013.03.007. Epub 2013 May 21.

PMID:
23701943
13.

Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.

Dalal BI, Mansoor S, Manna M, Pi S, Sauro GD, Hogge DE.

Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):274-9. doi: 10.1016/j.clml.2012.01.003. Epub 2012 Apr 4.

PMID:
22481022
14.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

15.

DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.

El Ghannam D, Taalab MM, Ghazy HF, Eneen AF.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):61-6. doi: 10.1016/j.bcmd.2014.01.004. Epub 2014 Feb 8.

PMID:
24512939
16.

[Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].

Li L, Lyu XD, Mi RH, Ding J, Chen L, Wang Q, Yin QS, Hu JY, Fan RH, Wei XD.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):601-6. doi: 10.7534/j.issn.1009-2137.2013.03.013. Chinese.

PMID:
23815906
17.

Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.

Sun Y, Shen H, Xu T, Yang Z, Qiu H, Sun A, Chen S, Wu D, Xu Y.

Leuk Res. 2016 Oct;49:102-7. doi: 10.1016/j.leukres.2016.09.001. Epub 2016 Sep 3.

PMID:
27626217
18.

Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.

Guo RJ, Atenafu EG, Schimmer AD, Minden MD, Chang H.

Int J Lab Hematol. 2017 Aug;39(4):429-437. doi: 10.1111/ijlh.12649. Epub 2017 Mar 20.

PMID:
28318150
19.

Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.

Xu Y, Sun Y, Shen H, Ding L, Yang Z, Qiu H, Sun A, Chen S, Wu D.

Am J Hematol. 2015 Nov;90(11):992-7. doi: 10.1002/ajh.24135.

20.

CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.

Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, Djokic M, Kant JA, Roth CG.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):212-7. doi: 10.1097/PAI.0b013e318261a342.

PMID:
22914610

Supplemental Content

Support Center